Back to Journals » Breast Cancer: Targets and Therapy » Volume 2

Role of trastuzumab in the management of HER2-positive metastatic breast cancer

Authors Milani A, Montemurro F, Gioeni L, Aglietta M, Valabrega G

Published 24 November 2010 Volume 2010:2 Pages 93—109

DOI https://doi.org/10.2147/BCTT.S6070

Review by Single-blind

Peer reviewer comments 2

Andrea Milani1,2, Filippo Montemurro1, Luisa Gioeni1, Massimo Aglietta1,2, Giorgio Valabrega1,2
1Oncological Department, Medical Oncology, Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino, Italy; 2University of Turin Medical School, Department of Biomedical Sciences and Human Oncology, Turin, Italy

Abstract: Breast cancer is a major health issue in developed countries. Overexpression of HER2, a member of epidermal growth factor receptor family, occurs in 20%–30% of breast cancers. HER2 drives the cancer cells to develop a more aggressive phenotype, to metastasize to viscera and central nervous system, and to be less sensitive to chemotherapeutic agents. Trastuzumab (Herceptin®) is a monoclonal antibody directed against the extracellular domain of HER2. As single agent or with chemotherapy, trastuzumab improves survival of HER2-positive breast cancers. In the past years, trastuzumab has completely revolutionized the scenario of the treatment of HER2-positive breast cancer, representing one of the most remarkable examples of targeted therapy in oncology. However, issues such as the best chemotherapeutic companion to associate with trastuzumab, cardiac toxicities, and clinical resistance still require tremendous efforts by researchers. Here, we review pharmacology, efficacy studies, and toxicities of trastuzumab in metastatic breast cancer. Moreover, we provide some insights on resistance to therapy. Finally, we briefly discuss trastuzumab’s place in the clinical setting.

Keywords: HER2, trastuzumab, breast cancer, cardiotoxicity, resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]